Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMEED for Unilateral Limbal Stem Cell Deficiency
NCT02649621Phase 1Completed
- Sponsor
- Royan Institute
- Start
- Aug 2011
- Primary completion
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of Amniotic membrane extract eye drops in limbal stem cell deficiency (LSCD), sponsored by Royan Institute. Primary endpoints: Limbal defect size at 12 months, Corneal epithelial integrity at 12 months and 1 more. Started Aug 2011; status: completed.
02
Drugs
Amniotic membrane extract eye drops
03
Conditions
limbal stem cell deficiency (LSCD)
Beyond the preview
Go deeper on NCT02649621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649621.